International Journal of
Reproductive Biomedicine
Thu, Dec 5, 2024
[Archive]
Volume 13, Issue 4 (5-2015)
IJRM 2015, 13(4): 231-236 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Adanaş Aydın G, Yavuz A, Terzi H, Kutlu T. Assessment of the relationship of basal serum anti-mullerian hormone levels with oocyte quality and pregnancy outcomes in patients undergoing ICSI. IJRM 2015; 13 (4) :231-236
URL: http://ijrm.ir/article-1-638-en.html
URL: http://ijrm.ir/article-1-638-en.html
1- Department of Obstetrics and Gynecology, Bursa Çekirge State Hospital, Bursa, Turkey
2- Department of Obstetrics and Gynecology, Kocaeli Derince Education and Research Hospital, Kocaeli, Turkey
3- Department of Obstetrics and Gynecology, Kocaeli Derince Education and Research Hospital, Kocaeli, Turkey ,drhterzi@yahoo.com
4- IVF Clinic, Zeynep Kamil Women's and Children's Hospital, Istanbul, Turkey
2- Department of Obstetrics and Gynecology, Kocaeli Derince Education and Research Hospital, Kocaeli, Turkey
3- Department of Obstetrics and Gynecology, Kocaeli Derince Education and Research Hospital, Kocaeli, Turkey ,
4- IVF Clinic, Zeynep Kamil Women's and Children's Hospital, Istanbul, Turkey
Abstract: (3694 Views)
Background: Anti-Mullerian hormone (AMH) is constantly secreted during menstrual cycles and may offer several advantages over traditional biomarkers of ovarian reserve.
Objective: To assess the relationship of anti-Mullerian hormone (AMH) values, which are used to evaluate ovary reserves, with oocyte and embryo quality and with ART outcomes in patients undergoing intra-cytoplasmic sperm injection (ICSI).
Materials and Methods: This cross sectional study was performed using 50 women undergoing ICSI in IVF center of Zeynep Kamil Women's and Children's Hospital, İstanbul, Turkey. All patients received the long protocol. Follicle-stimulating hormone, luteinizing hormone, estradiol, and AMH levels were measured and antral follicle counts were obtained on the 3 rd day of menstruation. A cut-off value based on the number of oocytes was determined for AMH, and women were evaluated after being divided into two groups as bad responders and good responders, according to their AMH levels.
Results: Twelve (27.3%) women were in bad responders group and 32 (72.7%) women were in good responders group. AMH measurements were statistically significantly different between the two groups (p<0.01). Based on this significance, the researchers used ROC analysis to estimate a cut-off point for AMH. The researchers detected the good responders with an AMH level 1.90 or above, with 87.50% sensitivity, 66.67% specificity, 87.50% positive prediction, and 66.67% negative prediction (AUC=0.777, p<0.01).
Conclusion: Basal AMH levels can be used as an indicator to determine the ovarian response in women undergoing ICSI. AMH can be used to predict the number of mature oocytes that can be collected during treatment and the number of oocytes that can be fertilized. However, AMH is not a valuable tool to evaluate oocyte quality, the development of high-quality embryos, or pregnancy conception.
Objective: To assess the relationship of anti-Mullerian hormone (AMH) values, which are used to evaluate ovary reserves, with oocyte and embryo quality and with ART outcomes in patients undergoing intra-cytoplasmic sperm injection (ICSI).
Materials and Methods: This cross sectional study was performed using 50 women undergoing ICSI in IVF center of Zeynep Kamil Women's and Children's Hospital, İstanbul, Turkey. All patients received the long protocol. Follicle-stimulating hormone, luteinizing hormone, estradiol, and AMH levels were measured and antral follicle counts were obtained on the 3 rd day of menstruation. A cut-off value based on the number of oocytes was determined for AMH, and women were evaluated after being divided into two groups as bad responders and good responders, according to their AMH levels.
Results: Twelve (27.3%) women were in bad responders group and 32 (72.7%) women were in good responders group. AMH measurements were statistically significantly different between the two groups (p<0.01). Based on this significance, the researchers used ROC analysis to estimate a cut-off point for AMH. The researchers detected the good responders with an AMH level 1.90 or above, with 87.50% sensitivity, 66.67% specificity, 87.50% positive prediction, and 66.67% negative prediction (AUC=0.777, p<0.01).
Conclusion: Basal AMH levels can be used as an indicator to determine the ovarian response in women undergoing ICSI. AMH can be used to predict the number of mature oocytes that can be collected during treatment and the number of oocytes that can be fertilized. However, AMH is not a valuable tool to evaluate oocyte quality, the development of high-quality embryos, or pregnancy conception.
Type of Study: Original Article |
References
1. Verlinsky Y, Cieslak J, Ivakhnenko V. Prevention of age-related aneuploidies by polar body testing of oocytes. J Assist Reprod Genet 1999; 16: 165-169. [DOI:10.1023/A:1020304621338]
2. Teixeria J, Mahesweran S, Donahoe PK. Müllerian inhibiting substance: an instructive developmental hormone with diagnostic and possible therapeutic applications. Endocr Rev 2001; 22: 657-674.
3. Durlinger AL, Gruijters MJ, Kramer P, Karels B, IngrahamHA, Nachtigal MW, et al. Anti-Mullerian hormone inhibit sinitiation of primordial follicle growth in the Mouse ovary. Endocrinology 2002; 143: 1076-1084. [DOI:10.1210/endo.143.3.8691]
4. Arabzadeh S, Hossein G, Rashidi BH, Hosseini MA, Zeraati H. Comparing serum basal and follicular fluid levels of anti-Mullerian hormone as a predictor of in vitro fertilization outcomes in patients with and without polycystic ovary syndrome. Ann Saudi Med 2010; 30: 442-447.
5. Seifer DB, MacLaughlin DT, Christian BP. Early follicular serum MIS levels are associated with ovarian response during ART cycles. Fertil Steril 2002; 77: 468-471. [DOI:10.1016/S0015-0282(01)03201-0]
6. Van Rooij IAJ, Broekmans FJM, te Velde ER, Fauser BCJM, Bancsi LFJMM, de Jong FH. Serum anti-Müllerian hormone levels: a novel measure of ovarian reserve. Hum Reprod 2002; 17: 3065-3071. [DOI:10.1093/humrep/17.12.3065]
7. Velde ER, Pearson PL. The variability of female reproductive aging. Hum Reprod 2002; 8: 141-154. [DOI:10.1093/humupd/8.2.141]
8. Bukman A, Heineman MJ. Ovarian reserve testing and the use of prognostic models in patients with subfertility. Hum Reprod 2001; 7: 581-590. [DOI:10.1093/humupd/7.6.581]
9. VanRooij IA, Broekmans FJ, Scheffer GJ. Serum AMH levels best reflect there productive decline with age in normal women with proven fertility: a longitudinal study. Fertil Steril 2005; 83: 979-987. [DOI:10.1016/j.fertnstert.2004.11.029]
10. Fıçıcıoğlu C, Kutlu T, Bakacak Z. Early folliculer AMH hormone as an indicator of ovarian reserve. Fertil Steril 2006; 85: 592-596. [DOI:10.1016/j.fertnstert.2005.09.019]
11. Hazout A, Bouchard P, Seifer DB. Serum MH appears to be a more discriminatory marker of assisted reproductive technology outcome than FSH, inhibin B, or estradiol. Fertil Steril 2004; 82: 1323-1329. [DOI:10.1016/j.fertnstert.2004.03.061]
12. Lekamge DN, Barry M, Kolo M. AMH as a predictor for IVF outcome. Reprod Biomed Online 2007; 14: 602-610. [DOI:10.1016/S1472-6483(10)61053-X]
13. Smeenk JM, Sweep FC, Zielhuis GA. AMH predicts ovarian responsiveness, but not embryo quality or pregnancy, after IVF or ICSI. Fertil Steril 2007; 87: 223-226. [DOI:10.1016/j.fertnstert.2006.06.019]
14. Eldar-Geva T, Ben-Chetrit A, Spitz IM. Dynamic assays of inhibin B, AMH and estradiol following FSH stimulation and ovarian ultrasonography as predictors of IVF outcome. Hum Reprod 2005; 20: 3178-3183. [DOI:10.1093/humrep/dei203]
15. Silberstein T, MacLaughlin DT, Shai I. MIS levels at the time of HCG administration in IVF cycles predicts both ovarian reserve and embryo morphology. Hum Reprod 2006; 21: 159-163. [DOI:10.1093/humrep/dei270]
16. Takahashi C, Fujito A, Kazuka M. AMH substance from follicular fluid is positively associated with success in oocyte fertilization during IVF. Fertil Steril 2008; 89: 586-591. [DOI:10.1016/j.fertnstert.2007.03.080]
17. Ebner T, Sommergruber M, Moser M. Basal level of anti-Müllerian hormone is associated with oocyte quality in stimulated cycles. Hum Reprod 2006; 21: 2022-2026. [DOI:10.1093/humrep/del127]
18. Setti AS, Figueira RCS, Braga DPAF, Colturato SS, Iaconelli Jr A, Borges Jr E. Relationship between oocyte abnormal morphology and intracytoplasmic sperm injection outcomes: a meta-analysis. Eur J Obstet Gynecol Reprod Biol 2011; 159: 364-370. [DOI:10.1016/j.ejogrb.2011.07.031]
19. Figueira RD, de Almeida Ferreira Braga DP, Semiao-Francisco L, Madaschi C, Iaconelli Jr A, Borges Jr E. Metaphase II human oocyte morphology: contributing factors and effects on fertilization potential and embryo developmental ability in ICSI cycles. Fertil Steril 2010; 94: 1115-1117. [DOI:10.1016/j.fertnstert.2009.11.039]
20. Boomsmaand CM, Macklon NS. What can the clinician do to improve implantation? Reprod Biomed Online 2006; 13: 845-855. [DOI:10.1016/S1472-6483(10)61034-6]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
